Three Cases of Long-Lasting Tumor Control with Erlotinib after Progression with Gefitinib in Advanced Non-Small Cell Lung Cancer
Explore this paper's citation graph
Summary
Elotinib may be effective in patients with non-small cell lung cancer who were previously and successfully treated with gefitinib, however, careful selection of these patients is needed.
- Type
- article
- Published
- 2007-08-01
- Cited by
- 38
- References
- 17
- Access
- Open access
- OpenAlex
- https://openalex.org/W2028069016
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:43917716
Keywords
Medicine, Gefitinib, Erlotinib, Lung cancer, Oncology
References
- Erlotinib in lung cancer - molecular and clinical predictors of outcome.
- Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib
- Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer.
- Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma.
- Gefitinib response of erlotinib-refractory lung cancer involving meninges—role of EGFR mutation
- Anticancer drugs: To the rescue?
- Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
- Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs.
- Erlotinib in previously treated non-small-cell lung cancer.
- Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.
- Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutations on the Outcome of Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
- Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib
- Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Cited by
- Contribution of the integrative pathology to the discovery of biomarkers for non-small cell lung cancer : integrative pathology and lung cancer
- Management of advanced non-small cell lung cancer: moving towards a more personalised approach
- Gefitinib versus erlotinib as salvage treatment for lung adenocarcinoma patients who benefited from the initial gefitinib: A retrospective study
- Salvage treatment with erlotinib after gefitinib failure in advanced non‐small‐cell lung cancer patients with poor performance status: A matched‐pair case–control study
- Subsequent treatment choices for patients with acquired resistance to EGFR-TKIs in non-small cell lung cancer: restore after a drug holiday or switch to another EGFR-TKI?
- Experimental treatment of brain metastases
- Antitumor activity of a novel EGFR tyrosine kinase inhibitor against human lung carcinoma in vitro and in vivo
- Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
- Gefitinib is effective for pathological fracture of metastatic non-small cell lung cancer
- Erlotinib after Failure of Gefitinib in Patients with Advanced Non-small Cell Lung Cancer Previously Responding to Gefitinib
- Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer.
- Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature.
- Orbital Metastases as the First Manifestation of Lung Adenocarcinoma
- Effects of Erlotinib after Acquired Resistance to Gefitinib in Advanced Non-small-cell Lung Cancer
- Antitumor Activity of a New N-Substituted Thiourea Derivative, an EGFR Signaling-Targeted Inhibitor against a Panel of Human Lung Cancer Cell Lines
- Anti-tumor activity of a novel EGFR tyrosine kinase inhibitor against human NSCLC in vitro and in vivo.
- Successful Rechallenge with Gefitinib for an Initial Erlotinib-Responder with Advanced Lung Adenocarcinoma.
- 多西他赛与吉非替尼序贯应用对人肺腺癌细胞H1975存活及凋亡通路的研究
- Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis
- Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer.
Related papers
- Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus
- Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment
- Comparison of the therapeutic outcome between gefitinib and erlotinib in female patients with non-small-cell lung cancer
- Sequential responses of adenocarcinoma of the lung to erlotinib after gefitinib in never smoker Korean woman.
- Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
- A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
- Long-term survival of non-small-cell lung cancer patients with EGFR inhibitor treatment.
- Clinical effect and pharmacoeconomics of gefitinib and erlotinib in advanced non-small-cell lung cancer
- Effectiveness of Erlotinib in Advanced Non-Small Cell Lung Cancer in Cases of Gefitinib Resistance after Treatment of More Than 6 Months